Stock·NASDAQ·Financial Services
Huntington Bancshares (HBAN)
- Market cap
- $31.78B
- P/E
- 12.10
- Dividend yield
- 3.94%
- Street target
- $19.00median of 21 analysts
- 52-week range
- $14.82 $19.46
HBAN stock forecast today
Where HBAN stands today, and what CleaRank Financial AI makes of it.
HBAN at a glance
Huntington Bancshares (HBAN): Hold, 58/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($16.09 and $16.73).
- Earnings HBAN beat estimates in 3 of the 7 reports in our data, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $9.9M and bought $852K over the last 18 months.
- Valuation P/E of 12.1 against 16.5 for the Financial Services sector: a discount to peers (-27%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Huntington Bancshares (HBAN) Hold with a model score of 58/100.
The analysts' outlook lifts the score the most: 15 of 21 analysts rate the stock a buy, and the median target is 20.8% above the price. The trend pulls it down the most, with the price 5.99% below its 200-day average and 2.26% below its 50-day average, and the 50-day average 3.82% below the 200-day. The 50-day stands at $16.09 and the 200-day at $16.73. Across the past year the price fell 2.12%.
Only on CleaRank
Figures we compute ourselves from HBAN's own price, earnings and insider-filing history. Tap one to see it in context.
HBAN stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $15.73 is 2.3% below the 50-day simple moving average of $16.09.Price above its 200-day average ›
The price is 6.0% below the 200-day simple moving average of $16.73.50-day average above the 200-day ›
The 50-day average ($16.09) is 3.8% below the 200-day average ($16.73), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 20% of its 52-week range, between $14.82 and $19.46.
HBAN share price
Pick a period: each tab shows how far HBAN has moved over it, to the last close.
Today's trading
Where HBAN sits inside today's range and its 52-week range.
HBAN fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 12.10 is 26.7% below the Financial Services median of 16.5.P/S below the sector median ›
The price-to-sales ratio of 3.23 is 14.9% below the sector median of 3.8.Profitable over the last 12 months ›
Net income over the last 12 months was $2.3B on revenue of $9.8B, a net margin of 23.6%.Beat estimates in most recent reports ›
HBAN beat the EPS estimate in 3 of the 7 reports in our data.Pays a dividend ›
The trailing dividend yield is 3.94%, or $0.62 a share a year.
Key statistics
The headline figures for HBAN.
As of October 26, 2026, HBAN trades at $15.73, with a market value of $31.78B, a P/E ratio of 12.10 and a dividend yield of 3.94%.
What the numbers say
CleaRank Financial AI's reading of HBAN's valuation, growth and risks.
HBAN trades at 12.10 times trailing earnings, which is 26.7% below the Financial Services median of 16.5. The peer comparison on this page calls that a discount to peers. Against sales, its P/S of 3.23 is 15.0% below the sector median P/S of 3.8. Trailing earnings stand at $1.30 a share.
Margins stand at a net margin of 23.6% and an operating margin of 39.81%. It reports a return on equity of 9.19%, below the sector median of 13.8%. A trailing dividend yield of 3.94% ($0.62 a share a year) rounds out the fundamentals.
The October 22, 2026 report came in line with expectations: EPS of $0.38 against an estimate of $0.38. The stock still rose 0.45% in the next session.
HBAN has beaten the EPS estimate in 3 of the 7 reports in our data, yet those beats have not guaranteed a higher share price, since the stock fell the next session after 2 of them. Analysts expect EPS of $1.55 for this fiscal year and $1.75 for next, with the current year showing growth of 6.0%.
HBAN's daily returns have a 30-day standard deviation of 1.49%, and its beta against the S&P 500 is 0.97. Because the price remains under both moving averages, the downtrend is a risk in its own right. The price is 19.17% below the 52-week high of $19.46. Insider sales over the last 18 months came to $9.9M, while open-market purchases came to $852K. Sales can be planned in advance or made to cover tax on vesting shares, so buying is the more telling signal.
HBAN against the Financial Services sector
How HBAN compares with the median Financial Services stock CleaRank tracks.
Price to earnings vs sector: HBAN trades at a notable discount to sector peers (-27%), which may indicate undervaluation or specific company headwinds.
Return vs XLF: Since May 14, 2025, HBAN has lost 2.2% against a gain of 10.0% for XLF.
Performance against XLF
HBAN and the Financial Services sector fund over the same days.
Revenue and earnings
How much HBAN sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); HBAN reported again on October 22, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 10.1% in FY2025 to $8.1B, from $7.4B a year earlier.
Profit margin: The net margin was 27.4% in FY2025, up from 26.5% the year before.
Profitable: HBAN earned $2.2B in FY2025.
Earnings reality check
Did HBAN beat what analysts expected, and how did the stock react?
Earnings record: HBAN beat the analyst estimate in 3 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 2 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 22, 2026after close | $0.38 | $0.38 | +0.00% | +0.45% | - |
| Jul 23, 2026after close | $0.39 | $0.39 | +0.00% | -0.23% | -1.84% |
| Apr 23, 2026after close | $0.35 | $0.37 | +5.71% | -2.55% | -0.42% |
| Jan 22, 2026after close | $0.38 | $0.37 | -2.63% | -1.64% | -1.98% |
| Jul 18, 2025after close | $0.35 | $0.35 | +0.00% | +0.60% | +0.78% |
| Apr 17, 2025after close | $0.31 | $0.34 | +9.68% | -1.46% | +5.34% |
| Jan 17, 2025after close | $0.32 | $0.33 | +3.13% | +0.53% | +0.94% |
As of October 26, 2026, HBAN has beaten the analyst EPS estimate in 3 of the 7 reports in our data and fell in the first trading session after 2 of those beats; its latest report, on October 22, 2026, came in 0.00% above the estimate and the stock moved +0.45% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
HBAN AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 52.5, in neutral territory.RSI above 50 ›
An RSI of 52.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of HBAN
The score, the reasoning behind it, and what could move the price next.
HBAN is in a downtrend, with both moving averages above the price. The price of $15.73 sits 2.26% below the 50-day average of $16.09 and 5.99% below the 200-day average of $16.73. Within its 52-week range the price is at 20%, and it is 6.14% above the 52-week low of $14.82. The two averages point the same way, with the 50-day 3.82% below the 200-day.
Recent gains sit on top of a weaker longer-term record. Over the past month the price rose 0.58%, but over the past three months it fell 8.33% and over the past year it fell 2.12%. In the last session the price rose 0.00% on volume that was 34.6% below its average. Momentum is neutral: the 14-day RSI is 52.5, in the neutral zone, and the MACD line is negative.
Earnings in line ›
The October 22, 2026 report came in line with the EPS estimate, and the share price rose 0.45% in the first session after it.
Source: Earnings report, October 22, 2026New analyst coverage ›
TD Cowen restarted coverage at Buy on October 8, 2026.
Source: Analyst action, TD Cowen, October 8, 2026
- Keep an eye on the two nearest levels. The 50-day SMA at $16.09 is above the price, and the 20-day EMA at $15.55 is below it.
- The 14-day RSI is 52.5, in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- In the first session after the October 22, 2026 report, the share price rose 0.45%. Over the 7 reports in our data, HBAN beat estimates in 3 of them.
HBAN remains in a downtrend while it sits below both its 50-day average of $16.09 and its 200-day average of $16.73. A close back above the 50-day would be the first sign of a repair. That 50-day SMA at $16.09 is the first hurdle above the price.
The first level below the price is the 20-day EMA at $15.55. The 14-day RSI of 52.5 sits in neutral territory, between 40 and 60.
Technical indicators
Momentum and trend for HBAN, from its daily closes.
As of October 26, 2026, with HBAN at $15.73, its 14-day RSI is 52.5 (neutral territory), its 50-day simple moving average is $16.09 and its 200-day is $16.73.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What HBAN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, HBAN's 1-year correlation of daily returns is +0.62 with S&P 500 (SPY), +0.48 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and +0.03 with gold (XAU).
HBAN price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
15 of 21 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $19.00 is 20.8% above the price.More buy ratings than three months ago ›
15 of 21 rate it a buy now, against 12 of 19 three months ago.
HBAN Wall Street View
12-month price targets
The price, $15.73, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 8, 2026 | TD Cowen | Reinstates | Buy |
| Oct 6, 2026 | Keefe, Bruyette & Woods | Maintains | Market Perform |
| Oct 5, 2026 | UBS | Maintains | Buy |
| Oct 2, 2026 | JP Morgan | Maintains | Overweight |
| Sep 23, 2026 | Truist Securities | Maintains | Buy |
| Sep 21, 2026 | DA Davidson | Maintains | Buy |
As of October 26, 2026, 21 Wall Street analysts cover HBAN: 15 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $17.00 to $22.50. The median HBAN price target is $19.00, 20.8% above the price of $15.73.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
HBAN trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
HBAN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from HBAN's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much HBAN tends to move, against the market and on its own.
HBAN price history and drawdowns
HBAN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.49% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 51.3%, from September 2018 to May 2020, regained by January 2021.Most 1-year holds ended higher ›
58% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $22,126, against $42,015 in the S&P 500 (SPY).
HBAN Drawdowns & Recovery
As of October 26, 2026, HBAN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.3% (September 2018 to May 2020); it regained that peak by January 2021, 8 months after the low, and 58% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HBAN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: HBAN trailed the S&P 500 over this period: $22,126 against $42,015.
A $10,000 investment in HBAN in October 2016 would be worth about $22,126 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HBAN, and which have not.
Strongest month, November: an average of +7.58%, up in 9 of 10 years.
Weakest month, March: an average of -8.92%, up in 2 of 10 years.
This month, October: has averaged +1.43%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, HBAN's strongest calendar month has been November (average +7.58%, up in 9 of 10 years) and its weakest March (average -8.92%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
HBAN stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HBAN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in HBAN today could grow to about $12,236 by 2030 in the base case, with a 90th-percentile outcome near $29,523 and a 10th-percentile outcome around $5,071. The simulation models price only; at today's 3.94% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
HBAN Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $19.25 for HBAN by 2030 in the base case, from $15.73 today (1.2x over 4 years). The 10th-percentile path ends near $7.98. These are outcomes of a Monte Carlo simulation run on HBAN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $10.65 | $16.54 | $25.70 | |
| 2028 | $9.33 | $17.40 | $32.44 | |
| 2029 | $8.53 | $18.30 | $39.24 | |
| 2030 | $7.98 | $19.25 | $46.44 |
Method: a lognormal simulation of HBAN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
HBAN insider trading
What the people running the company have bought and sold.
HBAN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $852K on the open market and sold $9.9M.
As of October 26, 2026, HBAN insiders reported 16 open-market sales worth $9.9M and 3 open-market purchases worth $852K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Ann B Crane
Director
|
Grant | 2.7K | - |
| Oct 1, 2026 | Amit Dhingra
Officer
|
Grant | 796 | - |
| Oct 1, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 859 | - |
| Oct 1, 2026 | Virginia A Hepner
Director
|
Grant | 95 | - |
| Oct 1, 2026 | Marcy C Hingst
Officer
|
Grant | 2.3K | - |
| Oct 1, 2026 | John C Inglis
Director
|
Grant | 1.3K | - |
| Oct 1, 2026 | Scott D Kleinman
Officer
|
Grant | 2.2K | - |
| Oct 1, 2026 | Katherine M. A. Kline
Director
|
Grant | 1.1K | - |
| Oct 1, 2026 | Kendall A Kowalski
Chief Technology Officer
|
Grant | 786 | - |
| Oct 1, 2026 | Nancy E. Maloney
Officer
|
Grant | 1.7K | - |
| Oct 1, 2026 | Timothy W Miller
Officer
|
Grant | 680 | - |
| Oct 1, 2026 | Prashant Nateri
Officer
|
Grant | 571 | - |
| Oct 1, 2026 | Richard W Neu
Director
|
Grant | 3.1K | - |
| Oct 1, 2026 | Kenneth J. Phelan
Director
|
Grant | 1.7K | - |
| Oct 1, 2026 | Sarah E Pohmer
Officer
|
Grant | 1.7K | - |
| Oct 1, 2026 | David L Porteous
Director
|
Grant | 3.6K | - |
| Oct 1, 2026 | Alice L Rodriguez
Director
|
Grant | 95 | - |
| Oct 1, 2026 | Senthilkumar Santhanakrishnan
Officer
|
Grant | 852 | - |
| Oct 1, 2026 | Teresa H Shea
Director
|
Grant | 431 | - |
| Oct 1, 2026 | Roger J. Sit
Director
|
Grant | 2.4K | - |
| Oct 1, 2026 | Brantley J Standridge
President
|
Grant | 2.8K | - |
| Oct 1, 2026 | Stephen D Steinour
Chief Executive Officer
|
Grant | 7.8K | - |
| Oct 1, 2026 | Jeffrey L. Tate
Director
|
Grant | 686 | - |
| Oct 1, 2026 | Zachary Jacob Wasserman
Officer
|
Grant | 2.7K | - |
| Oct 1, 2026 | Donnell R White
Officer
|
Grant | 207 | - |
| Aug 3, 2026 | Kendall A Kowalski
Chief Technology Officer
|
Sell | 28.0K | $481.1K |
| Jul 28, 2026 | Ann B Crane
Director
|
Grant | 1.8K | - |
| Jul 28, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 2.5K | - |
| Jul 28, 2026 | Richard W Neu
Director
|
Grant | 3.0K | - |
| Jul 28, 2026 | Teresa H Shea
Director
|
Grant | 865 | - |
| Jul 28, 2026 | Roger J. Sit
Director
|
Grant | 1.8K | - |
| Jul 1, 2026 | Ann B Crane
Director
|
Grant | 2.2K | - |
| Jul 1, 2026 | Amit Dhingra
Officer
|
Grant | 661 | - |
| Jul 1, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 687 | - |
| Jul 1, 2026 | Virginia A Hepner
Director
|
Grant | 79 | - |
| Jul 1, 2026 | Marcy C Hingst
General Counsel
|
Grant | 1.9K | - |
| Jul 1, 2026 | John C Inglis
Director
|
Grant | 1.1K | - |
| Jul 1, 2026 | Scott D Kleinman
Officer
|
Grant | 1.8K | - |
| Jul 1, 2026 | Katherine M. A. Kline
Director
|
Grant | 896 | - |
| Jul 1, 2026 | Kendall A Kowalski
Chief Technology Officer
|
Grant | 652 | - |
| Jul 1, 2026 | Nancy E. Maloney
Officer
|
Grant | 1.4K | - |
| Jul 1, 2026 | Timothy W Miller
Officer
|
Grant | 639 | - |
| Jul 1, 2026 | Prashant Nateri
Chief Operating Officer
|
Grant | 475 | - |
| Jul 1, 2026 | Richard W Neu
Director
|
Grant | 2.5K | - |
| Jul 1, 2026 | Kenneth J. Phelan
Director
|
Grant | 1.4K | - |
| Jul 1, 2026 | Sarah E Pohmer
Officer
|
Grant | 1.4K | - |
| Jul 1, 2026 | David L Porteous
Director
|
Grant | 3.0K | - |
| Jul 1, 2026 | Alice L Rodriguez
Director
|
Grant | 79 | - |
| Jul 1, 2026 | Senthilkumar Santhanakrishnan
Officer
|
Grant | 708 | - |
| Jul 1, 2026 | Teresa H Shea
Director
|
Grant | 349 | - |
| Jul 1, 2026 | Roger J. Sit
Director
|
Grant | 2.0K | - |
| Jul 1, 2026 | Brantley J Standridge
Officer
|
Grant | 2.3K | - |
| Jul 1, 2026 | Stephen D Steinour
Chief Executive Officer
|
Grant | 6.5K | - |
| Jul 1, 2026 | Jeffrey L. Tate
Director
|
Grant | 570 | - |
| Jul 1, 2026 | Zachary Jacob Wasserman
Chief Financial Officer
|
Grant | 2.2K | - |
| Jul 1, 2026 | Donnell R White
Officer
|
Grant | 171 | - |
| Jun 25, 2026 | Marcy C Hingst
General Counsel
|
Sell | 10.6K | $190.2K |
| Jun 12, 2026 | James D Rollins III
Director
|
Sell | 223.5K | $3.9M |
| Jun 1, 2026 | Scott D Kleinman
Officer
|
Sell | 19.4K | $314.7K |
| May 1, 2026 | Ann B Crane
Director
|
Grant | 9.3K | - |
| May 1, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 10.5K | - |
| May 1, 2026 | Virginia A Hepner
Director
|
Grant | 9.3K | - |
| May 1, 2026 | John C Inglis
Director
|
Grant | 10.5K | - |
| May 1, 2026 | Katherine M. A. Kline
Director
|
Grant | 9.3K | - |
| May 1, 2026 | Richard W Neu
Director
|
Grant | 10.5K | - |
| May 1, 2026 | Kenneth J. Phelan
Director
|
Grant | 10.5K | - |
| May 1, 2026 | David L Porteous
Director
|
Grant | 10.5K | - |
| May 1, 2026 | Alice L Rodriguez
Director
|
Grant | 9.3K | - |
| May 1, 2026 | Teresa H Shea
Director
|
Grant | 9.3K | - |
| May 1, 2026 | Roger J. Sit
Director
|
Grant | 9.3K | - |
| May 1, 2026 | Jeffrey L. Tate
Director
|
Grant | 9.3K | - |
| Apr 29, 2026 | Stephen D Steinour
Chief Executive Officer
|
Option | 25.3K | $254.6K |
| Apr 28, 2026 | Ann B Crane
Director
|
Grant | 1.9K | - |
| Apr 28, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 2.6K | - |
| Apr 28, 2026 | Richard W Neu
Director
|
Grant | 3.1K | - |
| Apr 28, 2026 | Teresa H Shea
Director
|
Grant | 902 | - |
| Apr 28, 2026 | Roger J. Sit
Director
|
Grant | 1.9K | - |
| Apr 1, 2026 | Ann B Crane
Director
|
Grant | 2.4K | - |
| Apr 1, 2026 | Amit Dhingra
Officer
|
Grant | 746 | - |
| Apr 1, 2026 | Rafael Andres Diaz-Granados
Director
|
Grant | 648 | - |
| Apr 1, 2026 | Marcy C Hingst
General Counsel
|
Grant | 2.1K | - |
| Apr 1, 2026 | Helga S Houston
Officer
|
Grant | 6.2K | - |
| Apr 1, 2026 | John C Inglis
Director
|
Grant | 1.1K | - |
| Apr 1, 2026 | Scott D Kleinman
Officer
|
Grant | 2.1K | - |
| Apr 1, 2026 | Katherine M. A. Kline
Director
|
Grant | 922 | - |
| Apr 1, 2026 | Kendall A Kowalski
Chief Technology Officer
|
Grant | 737 | - |
| Apr 1, 2026 | Brendan A Lawlor
Officer
|
Grant | 427 | - |
| Apr 1, 2026 | Nancy E. Maloney
Officer
|
Grant | 1.6K | - |
| Apr 1, 2026 | Timothy W Miller
Officer
|
Grant | 722 | - |
| Apr 1, 2026 | Prashant Nateri
Chief Operating Officer
|
Grant | 536 | - |
| Apr 1, 2026 | Richard W Neu
Director
|
Grant | 2.7K | - |
| Apr 1, 2026 | Kenneth J. Phelan
Director
|
Grant | 1.5K | - |
| Apr 1, 2026 | Sarah E Pohmer
Officer
|
Grant | 1.8K | - |
| Apr 1, 2026 | David L Porteous
Director
|
Grant | 3.3K | - |
| Apr 1, 2026 | Senthilkumar Santhanakrishnan
Officer
|
Grant | 800 | - |
| Apr 1, 2026 | Teresa H Shea
Director
|
Grant | 295 | - |
| Apr 1, 2026 | Roger J. Sit
Director
|
Grant | 2.1K | - |
| Apr 1, 2026 | Brantley J Standridge
Officer
|
Grant | 2.9K | - |
| Apr 1, 2026 | Stephen D Steinour
Chief Executive Officer
|
Grant | 7.4K | - |
| Apr 1, 2026 | Jeffrey L. Tate
Director
|
Grant | 553 | - |
| Apr 1, 2026 | Zachary Jacob Wasserman
Chief Financial Officer
|
Grant | 2.5K | - |
| Apr 1, 2026 | Donnell R White
Officer
|
Grant | 193 | - |
| Mar 12, 2026 | Scott D Kleinman
Officer
|
Sell | 65.5K | $1.0M |
| Mar 12, 2026 | Prashant Nateri
Chief Operating Officer
|
Sell | 10.2K | $157.6K |
| Mar 12, 2026 | Stephen D Steinour
Chief Executive Officer
|
Buy | 32.3K | $500.0K |
| Mar 9, 2026 | Amit Dhingra
Officer
|
Grant | 21.6K | - |
| Mar 9, 2026 | Helga S Houston
Officer
|
Grant | 111.7K | - |
| Mar 9, 2026 | Scott D Kleinman
Officer
|
Grant | 118.3K | - |
| Mar 9, 2026 | Kendall A Kowalski
Chief Technology Officer
|
Grant | 21.8K | - |
| Mar 9, 2026 | Brendan A Lawlor
Officer
|
Grant | 9.7K | - |
| Mar 9, 2026 | Nancy E. Maloney
Officer
|
Grant | 18.4K | - |
| Mar 9, 2026 | Prashant Nateri
Chief Operating Officer
|
Grant | 10.7K | - |
| Mar 9, 2026 | Brantley J Standridge
Officer
|
Grant | 131.4K | - |
| Mar 9, 2026 | Stephen D Steinour
Chief Executive Officer
|
Grant | 433.7K | - |
| Mar 9, 2026 | Zachary Jacob Wasserman
Chief Financial Officer
|
Grant | 131.4K | - |
| Mar 6, 2026 | Scott D Kleinman
Officer
|
Option | 13.1K | $132.1K |
| Mar 2, 2026 | Amit Dhingra
Officer
|
Grant | 21.2K | - |
| Mar 2, 2026 | Marcy C Hingst
General Counsel
|
Grant | 41.1K | - |
| Mar 2, 2026 | Helga S Houston
Officer
|
Grant | 35.8K | - |
| Mar 2, 2026 | Scott D Kleinman
Officer
|
Grant | 53.0K | - |
Source: TwelveData, from SEC Form 4 filings
HBAN stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.